IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Invivyd, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.61−0.01 (-1.39%)

Close on Oct 19, 2026

Market cap: $195.47M
P/E (TTM): –
Dividend yield: –

Invivyd, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	53	25	0	–	–	–
Research & Development	38	137	159	179	183	–
Selling, General & Admin	67	63	49	47	37	–
Operating Expenses	109	202	213	248	227	–
Total Costs & Expenses	109	202	213	–	–	–
Operating Income	-56	-177	-213	-248	-227	–
Other Non-Operating Income	3.07	6.95	14	6.71	0.12	–
Asset Impairment Charges	0	0	0	0	0	0
Gain (Loss) on Investments	–	–	0	0	0	–
Income Tax Expense	0	0	0	0	0	–
Net Income incl. Noncontrolling Interests	-52	-170	-199	-241	-227	–
Net Income	-52	-170	-199	-241	-227	–
EPS (Basic)(per share)	-0.30	-1.43	-1.81	-2.23	-5.32	–
EPS (Diluted)(per share)	-0.30	-1.43	-1.81	-2.23	-5.32	–
Shares Outstanding (Basic, Weighted)(shares)	172	119	110	108	43	–
Shares Outstanding (Diluted, Weighted)(shares)	172	119	110	108	43	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -192.8%
Net margin: -183.9%
Return on equity, FY2025: -34.0%

Financial strength

Current ratio: 5.87
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 515.9%

Valuation

P/E ratio: –
Price to sales: 3.35
Price to book: 1.08
Dividend yield: –